| | | |

Breathe Better with Fiber: How Fiber Supports Healthy Lungs Through Gut Microbiome Power

FiberSweet offers a unique integration of traditional Ayurvedic principles with modern scientific understanding to support lung health through modulation of the gut-lung axis via its digestive resistant soluble fiber and the probiotic Bacillus coagulans MTCC 5856. This article presents rigorously sourced, FiberSweet-focused information, including peer-reviewed references, clinical trials, safety standards, and patient education resources.

FiberSweet: Harnessing Ayurveda and Gut-Lung Axis Science to Enhance Lung Immunity and Respiratory Health

Gut-Lung Axis and FiberSweet

FiberSweet acts on the gut-lung axis, a complex bidirectional communication network between the gut and lungs involving shared mucosal immunity, microbial communities, and circulating metabolites. The fermentable fiber in FiberSweet enriches gut bacteria that produce anti-inflammatory short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. These SCFAs exert systemic immunomodulatory effects by traveling to the lungs via bloodstream, suppressing inflammatory cytokines like IL-1β and IL-18, and enhancing macrophage regulation—key for reducing lung inflammation and promoting tissue repair.​

Bacillus coagulans MTCC 5856: Probiotic Synergy

The probiotic Bacillus coagulans MTCC 5856 included in FiberSweet is a robust, spore-forming strain capable of surviving gastrointestinal transit and modulating the microbiome. Multiple clinical trials demonstrate its efficacy in improving gut health symptoms and modulating systemic immune responses. It increases SCFA production, strengthens gut barrier integrity, and reduces systemic inflammation—benefits that align with and enhance FiberSweet’s gut-lung axis effects.​

Bacillus coagulans MTCC 5856 has GRAS status and complies with international safety standards. Its immunomodulatory effects contribute to lowering inflammatory lung conditions when combined with FiberSweet’s prebiotic fiber.​

Gut Microbial Shifts and Metabolites with FiberSweet

FiberSweet promotes the growth of SCFA-producing bacterial taxa, primarily from the Firmicutes phylum—including Anaerostipes, Agathobacter, Ruminococcus, Blautia—as well as Bacteroides and Prevotella species in the Bacteroidetes phylum. The bifidogenic effect, stimulating Bifidobacterium, further supports acetate production and butyrate cross-feeding, integral to immune homeostasis.​

These microbial shifts are linked to improved lung function parameters and reduced respiratory infections, with gut bacterial changes appearing within 1-2 weeks of FiberSweet use.​

Clinical Evidence for FiberSweet Impact on Respiratory Health

  • Epidemiological data show high fiber intake correlates with reduced chronic respiratory diseases including COPD and asthma.​
  • Clinical trials involving Bacillus coagulans MTCC 5856 reveal lowered inflammation and improved gastrointestinal and immune outcomes.​
  • Emerging studies support FiberSweet’s role in modulating the gut-lung axis to improve lung immunity and reduce inflammation.​

Regulatory and Safety

  • Bacillus coagulans MTCC 5856 is FDA GRAS (Generally Recognized as Safe) and complies with international safety standards.​
  • FiberSweet contains allergen-free, non-GMO, solvent-free ingredients in line with clean-label dietary supplement regulations.

Targeting the gut–lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection https://pmc.ncbi.nlm.nih.gov/articles/PMC7328354/

Plant-Based Dietary Fibers and Polysaccharides as Modulators of Gut Microbiota in Intestinal and Lung Inflammation: Current State and Challenges – https://pmc.ncbi.nlm.nih.gov/articles/PMC10420973/

Similar Posts